ImpediMed Limited announce the recent expansion of the use of its SOZO® Digital Health Platform at leading cancer centers dedicated to reducing the impact of lymphedema on breast cancer patients. Several key customers, including City of Hope, Mayo Clinic, University of Pittsburgh Medical Center, and US Oncology, added new SOZO devices or software licenses to expand access to SOZO testing for their breast cancer patients. Since the launch of the Lymphedema Prevention Program, ImpediMed has announced multiple partnerships with leading institutions globally.

Publication of ImpediMed's PREVENT Trial three-year primary endpoint results, which demonstrated that routine monitoring with L-Dex combined with at-home intervention resulted in a 92% reduction in lymphedema progression, also contributed to further adoption of SOZO for lymphedema prevention.